<DOC>
	<DOCNO>NCT01569841</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial compare efficacy insulin decludec insulin glargine glycaemic control use continuous glucose monitoring patient type 1 diabetes .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Insulin Degludec With Insulin Glargine Glycaemic Control Using Continuous Glucose Monitoring Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes HbA1c ( glycosylated haemoglobin ) equal 8.5 % Current treatment IGlar ( insulin glargine ) basalbolus regimen total daily dose 120 U BMI ( body mass index ) 35 kg/m^2 Use within last 3 month prior visit 1 ( screen ) antidiabetic glucose lower drug insulin/insulin analogue Subjects regular use acetaminophen willing use another analgetic CGM ( Continuous Glucose Monitoring ) period Stroke ; heart failure ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty within 24 week prior visit 1 Recurrent severe hypoglycemia ( one severe hypoglycemic event last 12 month ) hypoglycemia unawareness hospitalization diabetic ketoacidosis previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>